Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 20, 2012	STAHL NEIL SVP Res and Devel Sciences Trans History: 660	SVP Res and Devel Sciences	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	17,000	--	52,048
Sep 17, 2003	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 628	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Open market or private sale of non-derivative or derivative security	17,000	$20.25	113,651
Dec 23, 2014	Sanofi Ten Percent Owner Trans History: 555	Ten Percent Owner	Form 4	Open market or private purchase of non-derivative or derivative security	17,013	$386.45	22,692,701
Jul 08, 2014	Sanofi Ten Percent Owner Trans History: 555	Ten Percent Owner	Form 4	Open market or private purchase of non-derivative or derivative security	17,014	$312.12	21,360,275
Feb 25, 2020	Van Plew Daniel P EVP & General Mgr Industrial O Trans History: 359	EVP & General Mgr Industrial O	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	17,093	$447.30	43,893
Dec 23, 2005	GOLDBERG MURRAY A SVP Fin & Admin, CFO, & Treas Trans History: 645	SVP Fin & Admin, CFO, & Treas	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	17,098	$13.31	37,268
Aug 28, 2012	STAHL NEIL SVP Research and Development S Trans History: 660	SVP Research and Development S	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	17,099	$145.70	76,005
Jan 12, 2012	RYAN ARTHUR F Director Trans History: 547	Director	Form 4	Open market or private sale of non-derivative or derivative security	17,100	$79.09	67,355
Nov 29, 2012	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Open market or private sale of non-derivative or derivative security	17,155	$181.19	56,946
Dec 19, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs Trans History: 628	Director, EVP CSO Pres Regen Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	17,182	$11.64	1,099,101

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media